The Rifaximin Study in CVID
Primary Purpose
Common Variable Immunodeficiency (CVID)
Status
Completed
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Rifaximin
Sponsored by
About this trial
This is an interventional basic science trial for Common Variable Immunodeficiency (CVID)
Eligibility Criteria
Inclusion Criteria:
- 18 ≥ and <75 years of age
- A diagnosis of CVID: decreased serum levels (> 2 SD) of immunoglobulin (Ig)G, IgA and/or IgM and exclusion of other forms of hypogammaglobulinemia
Exclusion Criteria:
- Previous treatment with antibiotics within the last 12 weeks
- History of hypersensitivity to Rifaximin or other Rifamycin derived antimicrobial agents, or any of the components of XIFAXAN
- Comorbidity not related to CVID- i.e. conditions or symptoms that may influence with the patient safety or compromise the study results (e.g., cardiovascular disorders, alcoholism, psychiatric disease, HIV infection etc.)].
- Polypharmacy with increased risk for interactions. i.e. patient with an extensive medication lists (e.g. 10 drugs or more) this may influence with the patient safety or compromise the study results
- Malignancy of any cause
- Impaired kidney function (i.e., estimated glomerulus filtration rate <50 ml/minute/1.73 m2]
- Impaired liver function (Alanine aminotransferase > 150 U/l) or established liver cirrhosis.
- Pregnant or planning to be pregnant in the study period to avoid interference of pregnancy with gut microbiota (not because of toxicity].
- Nursing
- On-going infection, including GI infection
- The use of probiotics for the recent 6 months
- Any immunosuppressive drugs,
Sites / Locations
- Oslo University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
No treatment
Rifaximin
Arm Description
patient receive no active treatment
Patient takes Rifaximin 550mg twice daily for 14 days
Outcomes
Primary Outcome Measures
Changes in inflammatory and anti-inflammatory mediators
Changes in serum/plasma/whole blood of tumor necrosis factor alpha (TNF-alpha), c reactive protein (CRP), soluble CD14 and other cytokines/chemokines.
Secondary Outcome Measures
Full Information
NCT ID
NCT01946906
First Posted
September 12, 2013
Last Updated
April 23, 2015
Sponsor
Oslo University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01946906
Brief Title
The Rifaximin Study in CVID
Official Title
Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
October 2013 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with Common variable immunodeficiency (CVID) have various forms of autoimmune and auto inflammatory disorders. The study will investigate if intervention with Rifaximin modifies the gut microbiota with a subsequent alteration in markers of systemic immune activation and inflammation in patients with CVID. The investigators hypothesize that the gut microbiota of CVID patients, at least partly through interaction with the innate immune system within the intestine, contribute to a low-grade systemic inflammation in these patients, and that an intervention with the non-absorbable antibiotic Rifaximin attenuates systemic inflammation through modulation of the gut microbiota. The study may lead to increased understanding of the interaction between microbiota and the immune system. The study could give new insight into important disease processes in relation to the interaction between the microbiota, the intestine and the systemic compartment, and potentially be the basis of new therapeutic strategies in these patients to prevent and down-regulate the auto-inflammatory and autoimmune complications seen in CVID. The findings could also be of relevance for other disorders where the interaction between microbiota and intestinal and systemic inflammation is involved such as various cardiovascular and metabolic disorders.
The investigators hypothesize that the gut microbiota of CVID patients, at least partly through interaction with the innate immune system within the intestine, contribute to a low-grade systemic inflammation in these patients, and that an intervention with the non-absorbable antibiotic Rifaximin attenuates systemic inflammation through modulation of the gut microbiota.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Common Variable Immunodeficiency (CVID)
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
No treatment
Arm Type
No Intervention
Arm Description
patient receive no active treatment
Arm Title
Rifaximin
Arm Type
Experimental
Arm Description
Patient takes Rifaximin 550mg twice daily for 14 days
Intervention Type
Drug
Intervention Name(s)
Rifaximin
Other Intervention Name(s)
Xifaxan
Primary Outcome Measure Information:
Title
Changes in inflammatory and anti-inflammatory mediators
Description
Changes in serum/plasma/whole blood of tumor necrosis factor alpha (TNF-alpha), c reactive protein (CRP), soluble CD14 and other cytokines/chemokines.
Time Frame
after 2 and 8 weeks after Day 0
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 ≥ and <75 years of age
A diagnosis of CVID: decreased serum levels (> 2 SD) of immunoglobulin (Ig)G, IgA and/or IgM and exclusion of other forms of hypogammaglobulinemia
Exclusion Criteria:
Previous treatment with antibiotics within the last 12 weeks
History of hypersensitivity to Rifaximin or other Rifamycin derived antimicrobial agents, or any of the components of XIFAXAN
Comorbidity not related to CVID- i.e. conditions or symptoms that may influence with the patient safety or compromise the study results (e.g., cardiovascular disorders, alcoholism, psychiatric disease, HIV infection etc.)].
Polypharmacy with increased risk for interactions. i.e. patient with an extensive medication lists (e.g. 10 drugs or more) this may influence with the patient safety or compromise the study results
Malignancy of any cause
Impaired kidney function (i.e., estimated glomerulus filtration rate <50 ml/minute/1.73 m2]
Impaired liver function (Alanine aminotransferase > 150 U/l) or established liver cirrhosis.
Pregnant or planning to be pregnant in the study period to avoid interference of pregnancy with gut microbiota (not because of toxicity].
Nursing
On-going infection, including GI infection
The use of probiotics for the recent 6 months
Any immunosuppressive drugs,
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Borre Fevang, MD, Phd
Organizational Affiliation
Oslo University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oslo University Hospital
City
Oslo
Country
Norway
12. IPD Sharing Statement
Learn more about this trial
The Rifaximin Study in CVID
We'll reach out to this number within 24 hrs